GLP-1 Restores Altered Insulin and Glucagon Secretion in Posttransplantation Diabetes

Abstract

PTDM is characterized by reduced glucose-induced insulin secretion and attenuated glucagon suppression during a hyperglycemic clamp. Similar to the case in type 2 diabetes, GLP-1 infusion seems to improve (insulin) or even normalize (glucagon) these pathophysiological defects.